Ruth Ralbag - ICL Israel External Independent Director
| ICL Stock | ILA 2,246 49.00 2.23% |
Director
Ms. Ruth Ralbag serves External Independent Director at ICLIsrael Chemicals Ltd. since January 10, 2018. Her work experience includes the following roles Chief Financial Officer of Shaare Zedek Medical Center in Jerusalem, Deputy Director of Medical Finance at the Tel Aviv Sourasky Medical Center, Deputy Director General of Planning, Budget and Pricing at Israel Ministry of Health, Vice President and Head of Commercial and Retail Banking division at FIBI, Acting Chairperson of the Board at FIBI Mortgages Ltd., Acting Chairperson of the Board at Atzmaut Mortgage Bank Ltd. and Director at a variety of additional companies. She holds Directorship in various other companies. She holds a Bachelors degree in Economics and Business Administration and a Masters degree in Public Policy, both from The Hebrew University of Jerusalem. since 2018.
| Age | 59 |
| Tenure | 7 years |
| Phone | (972) 3 684 4427 |
| Web | www.icl-group.com |
ICL Israel Management Efficiency
The company has return on total asset (ROA) of 0.1916 % which means that it generated a profit of $0.1916 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4322 %, meaning that it generated $0.4322 on every $100 dollars invested by stockholders. ICL Israel's management efficiency ratios could be used to measure how well ICL Israel manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Perry Nisen | Teva Pharmaceutical Industries | 63 | |
| Dalya Lev | Bank Hapoalim | 71 | |
| Yehoshua Gleitman | Elbit Systems | 69 | |
| Roberto Mignone | Teva Pharmaceutical Industries | 47 | |
| Moshe Koren | Bank Hapoalim | 81 | |
| Rosemary Crane | Teva Pharmaceutical Industries | 59 | |
| Ehood Nisan | Elbit Systems | 51 | |
| Ruben Krupik | Bank Hapoalim | 67 | |
| Yuli Tamir | Elbit Systems | 65 | |
| JeanMichel Halfon | Teva Pharmaceutical Industries | 67 | |
| Ronit Rokach | Bank Hapoalim | 61 | |
| Richard Kaplan | Bank Hapoalim | 63 | |
| Noam Hanegbi | Bank Hapoalim | 61 | |
| Yoram BenZeev | Elbit Systems | 74 | |
| Gerald Lieberman | Teva Pharmaceutical Industries | 72 | |
| Dov Ninveh | Elbit Systems | 71 | |
| Rina Baum | Elbit Systems | 73 | |
| Nechemia Peres | Teva Pharmaceutical Industries | 60 | |
| Asaf Azulay | Bank Hapoalim | 35 | |
Management Performance
| Return On Equity | 0.43 | |||
| Return On Asset | 0.19 |
ICL Israel Chemicals Leadership Team
Elected by the shareholders, the ICL Israel's board of directors comprises two types of representatives: ICL Israel inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ICL. The board's role is to monitor ICL Israel's management team and ensure that shareholders' interests are well served. ICL Israel's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ICL Israel's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Raviv Zoller, Chief Executive Officer | ||
| Nitzan Moshe, Executive Vice President - Global Operations | ||
| Tzipi OzerArmon, Independent Director | ||
| Lilach GevaHarel, Senior Vice President and Global General Counsel | ||
| Avisar Paz, Director | ||
| Yoav Doppelt, Executive Chairman of the Board | ||
| Ilana Fahima, Executive Vice President ICL Global Human Resources | ||
| Ido Lilian, Executive Vice President-Global Procurement | ||
| Reem Aminoach, Independent Director | ||
| Ruth Ralbag, External Independent Director | ||
| Noam Goldstein, President - Potash Division | ||
| Anantha Desikan, Executive Vice President Chief Innovation & Technology Officer | ||
| Maya Grinfeld, VP Communications | ||
| Aviram Lahav, Chief Officer | ||
| Aya Landman, Company VP | ||
| Ofer Lifshitz, President, ICL Phosphate Solutions Division | ||
| Lior Reitblatt, Independent Director | ||
| Nadav Kaplan, Independent Director | ||
| Kobi Altman, CFO, Executive Vice President | ||
| Anat TalKtalav, President ICL Industrial Products Division | ||
| Eli Amon, Executive Vice President ICL Innovative Ag Solutions Division | ||
| Aviad Kaufman, Director | ||
| Miri Mishor, Senior Vice President - ICL Global Information Technology | ||
| Ovadia Eli, External Director | ||
| Amir Meshulam, Senior Vice President Global Internal Auditor | ||
| Advocate GevaHarel, Exec Counsel | ||
| Elad Aharonson, Pres Solutions | ||
| Sagi Kabla, Director |
ICL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ICL Israel a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.43 | |||
| Return On Asset | 0.19 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.34 % | |||
| Current Valuation | 43.75 B | |||
| Shares Outstanding | 1.29 B | |||
| Shares Owned By Insiders | 44.90 % | |||
| Shares Owned By Institutions | 25.12 % | |||
| Price To Book | 2.00 X | |||
| Price To Sales | 3.31 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in ICL Stock
When determining whether ICL Israel Chemicals is a strong investment it is important to analyze ICL Israel's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ICL Israel's future performance. For an informed investment choice regarding ICL Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ICL Israel Chemicals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.